X0306 4 2013-02-20 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532218 Patel Sanj K 128 SPRING STREET, SUITE 520 LEXINGTON MA 02421 true true false false President & CEO Common Stock 286 I Held by Abbey Road Investment Group Common Stock 2013-02-20 4 M false 18654 0.95 A 19685 D Common Stock 2013-02-20 4 M false 5954 0.95 A 25639 D Common Stock 2013-02-20 4 S false 18654 49.49 D 6985 D Common Stock 2013-02-20 4 S false 5954 49.6 D 1031 D Common Stock 2013-02-21 4 M false 45392 0.95 A 46423 D Common Stock 2013-02-21 4 S false 45392 49.02 D 1031 D Stock Option (Right to Buy) 0.95 2013-02-20 4 M false 18654 0 D 2019-07-01 Common Stock 18654 86650 D Stock Option (Right to Buy) 0.95 2013-02-20 4 M false 5954 0 D 2019-12-15 Common Stock 5954 102032 D Stock Option (Right to Buy) 0.95 2013-02-21 4 M false 45392 0 D 2019-07-01 Common Stock 45392 41258 D The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2012. The stock option granted the reporting person an option to purchase 396,070 Shares. 25% of such Shares vested and became exercisable on 07/01/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. The stock option granted the reporting person an option to purchase 117,220 Shares. 25% of such Shares vested and became exercisable on 09/25/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $48.80 to $49.42. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Chris Heberlig, Attorney-in-Fact 2013-02-22